Join our email list!

Get daily updates delivered to your inbox
Thank you for subscribing

Sanofi Enrolling for 2 GEMINI Trials Testing Tolebrutinib vs. Aubagio for Relapsing MS

Sanofi Enrolling for 2 GEMINI Trials Testing Tolebrutinib vs. Aubagio for Relapsing MS
4.2
(5)

Two global Phase 3 clinical trials, both comparing Sanofi Genzyme’s investigational tolebrutinib with its approved therapy Aubagio, are enrolling a total of 1,800 people with relapsing multiple sclerosis (MS), the company said.

All patients in both studies — dubbed GEMINI 1 and GEMINI 2 — will receive active treatment, the National Multiple Sclerosis Society announced in a press release.

Enrollment is taking place at multiple clinical sites across the U.S, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Korea, Estonia, Latvia, Puerto Rico, and Spain. More information and contacts can be found on the trials’ pages, here and here.

Tolebrutinib, previously known as SAR442168, is a small molecule inhibitor of the enzyme Bruton tyrosine kinase (BTK), which plays a key role in the activity and survival of immune B-cells. This subset of antibody-producing immune cells is thought to be one of the key drivers of inflammation in MS.

By blocking the activity of BTK and penetrating the brain, tolebrutinib is expected to help lower inflammation in the central nervous system (CNS), comprised of the brain and spinal cord.

The clinical trials, GEMINI 1 (NCT04410978) and GEMINI 2 (NCT04410991), are each enrolling 900 adults, ages 18 to 55, with relapsing MS, which includes relapsing-remitting MS and active secondary progressive MS.

The trials will assess the safety and efficacy of a daily oral dose of tolebrutinib compared to a 14 mg daily dose of Aubagio (teriflunomide), an approved MS therapy also marketed by Sanofi. The studies will be conducted for up to 36 months (three years).

The primary goal of these clinical studies is the reduction of MS relapses, as measured by the annualized relapse rate (ARR). Secondary goals include the effects of treatment on disability progression, disease activity on MRI scans, cognitive performance, quality of life, and laboratory biomarkers of immune and nervous system activity.

Since the studies will involve up to 16 in-person visits to a study site, precautions are being taken to reduce the risk of exposure to COVID-19. Of note, clinical site visits will include MRI scans, blood draws, clinical exams, and questionnaires.

To learn more about the enrollment and eligibility criteria of the GEMINI trials, call 1-800-633-1610 extension option 6, or email [email protected].

In June, the first participant was enrolled in the GEMINI 1 trial.

Sanofi also is conducting the HERCULES trial (NCT04411641), to assess the safety and efficacy of tolebrutinib, compared with a placebo, at delaying disability progression in up to 1,290 patients with non-relapsing (non-active) secondary progressive MS.

Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.
Total Posts: 1,053
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.
Latest Posts
  • MSTV channel
  • ANK-700 trial
  • mega-trial, multiple progressive MS trials
  • cooling vest

How useful was this post?

Click on a star to rate it!

Average rating 4.2 / 5. Vote count: 5

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?